Neurogene Posts $29.0M Q3 Loss, $359.7M Cash Through Q1 2029, Embolden Data 2H 2027
NGNE sits 59% above its 52-week low of $15.93.
Summary
Neurogene reported a $29.0 million Q3 2026 net loss, with $359.7 million in cash funding operations into Q1 2029. The Embolden registrational trial now includes all 25 dosed patients in the primary analysis, and topline data are expected in the second half of 2027.
Key Events · Earnings and Guidance · NGNE
-
Q3 Loss Widens on NGN-401 Spend
Net loss was $29.0 million for Q3 2026 versus $21.0 million a year earlier, driven by R&D of $23.5 million (up from $17.2 million) on Rett syndrome trial and CMC activities.
-
Cash Runway Into First Quarter 2029
Cash, cash equivalents and short-term investments totaled $359.7 million at September 30, 2026, expected to fund operations into Q1 2029 — past the Embolden readout and BLA submission.
-
Embolden Analysis Plan Expanded to 25 Patients
All 25 dosed participants are included in the primary efficacy analysis, with success set at 9 of 25 (36%) responders; the update was aligned with the FDA through the START Pilot Program.
-
Topline Data Expected Second Half 2027
Embolden registrational topline data are anticipated in 2H 2027, with BLA-enabling PPQ runs on track for completion by year-end 2026.
Analysis · NGNE · Life Sciences
This quarterly update is mostly a runway and timeline story. With $359.7 million in cash, operations are funded into the first quarter of 2029, covering the Embolden topline readout expected in the second half of 2027 and a planned BLA submission, so there is no near-term financing need. The one substantive change is the Embolden statistical plan: all 25 dosed participants now count in the primary efficacy analysis, and only 9 of 25 (36%) need to respond for success, a bar the Phase 1/2 data cleared at 80% (8 of 10). That lowers the binary risk on the registrational trial. Against that, the net loss widened to $29.0 million from $21.0 million a year ago on higher NGN-401 development and manufacturing spend, and the next hard catalyst is more than a year out.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NGNE was trading at $25.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $506.5M. The 52-week trading range was $15.93 to $43.66. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.